FEMY (Femasys) GF Value : $0.62 (As of Apr. 02, 2025)

View and export this data going back to 2021. Start your Free Trial

What is Femasys GF Value?

As of today (2025-04-02), Femasys's share price is $1.23. Femasys's GF Value is $0.62. Therefore, Femasys's Price-to-GF-Value for today is 1.98. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Femasys is Significantly Overvalued.

The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.

To calculate this value, GuruFocus follows these steps:

We analyze historical correlations between the stock price and key business performance metrics, such as revenue, earnings, cash flow, and book value.
We identify the metrics that have the strongest historical correlation with the stock price and determine the historical multiples at which the stock has traded relative to these metrics.
Using these historical multiples as a reference, we estimate the stock's fair value while accounting for future business growth. Adjustments may be made based on the company’s past returns and growth trends.

GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.

Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

Femasys (NAS:FEMY) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) A sufficient margin of safety exists only when the stock is undervalued.

Femasys's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.23	/	0.62
	=	1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Femasys GF Value Related Terms

Thank you for viewing the detailed overview of Femasys's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024

Website

https://www.femasys.com

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Executives

Keith J Kendall	director	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes	director	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas	officer: SVP, Regulatory & Clinical	2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash	officer: Chief Medical Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett	director, 10 percent owner	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr	director	35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko	director, 10 percent owner	4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen	director	28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick	director, officer: Chief Executive Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie	officer: Senior VP, Operations	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria	officer: VP, Clinical & Medical Affairs	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson	director	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte	director	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025